Volume 13 Supplement 4
O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
© Clumeck et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Patients with HIV RNA suppression below 50 copies/mL may still have HIV RNA detectable by more sensitive PCR assay techniques.
In the MONET trial, 256 patients with HIV RNA <50 copies/mL on current HAART, and no history of virological failure, switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTI (n=129). HIV RNA was evaluated by the Roche Amplicor Ultrasensitive assay (lower detection limit=50 copies/mL), for all patient visits to Week 96. With this assay, "Optical Density=background" was used to assess whether HIV RNA was detectable or undetectable below 50 copies/mL.
DRV/r mono (n=105)
DRV/r + 2NRTIs (n=114
HIV RNA <50, OD = background
HIV RNA <50, detectable
HIV RNA 50-400 copies/mL
HIV RNA <400 copies/mL
Including all samples from patient visits from Week 4 to Week 96, HIV RNA was above 50 copies/mL in 69/1009 samples in the DRV/r monotherapy arm (50-400: 84%, 400-1000: 12%, >1000: 4%) and 47/1051 samples in the DRV/r + 2NRTI arm (50-400: 83%, 400-1000: 8.5%, >1000: 8.5%).
In this study for patients with HIV RNA <50 copies/mL at baseline, switching to DRV/r monotherapy showed similar levels of HIV RNA suppression to DRV/r + 2NRTIs, using more sensitive PCR assay techniques.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.